August 19, 2021
Otsuka Pharmaceutical said on August 18 that its antipsychotic agent Rexulti (brexpiprazole) failed to hit the primary goal in a PII clinical study for the treatment of borderline personality disorder (BPD). The study, which was launched in 2019 together with...read more